MGMark A. Griffiths

Mark A. Griffiths

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark A. Griffiths has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    When Usability Isn’t Enough: Understanding Rural Challenges in Respiratory Virus Test Interpretation

    by Jennifer K. Frediani, Cheryl L. Stone, Sarah Farmer, Amanda Peagler, Richard Parsons, Adrianna L. Westbrook, Laura M. Johnson, Mark A. Griffiths, Wilbur A. Lam, Greg S. Martin

    Background/Objectives: This study aimed to evaluate the usability and comprehension of at-home respiratory diagnostic tests for COVID-19 and influenza among rural and urban populations in Georgia. It sought to identify disparities in test interpretation and outcomes that could inform public health interventions tailored to underserved communities. Methods: Participants with respiratory symptoms (N = 592) were enrolled through community events in three rural Georgia counties (N = 188) and urban clinics in Atlanta (N = 404). Structured usability assessments and RT-PCR-confirmed diagnostic testing were conducted. Demographic, clinical, and survey data were analyzed using t-tests, z-tests, and Fisher’s exact tests to compare rural and urban participants. Results: Rural participants were older and more likely to be White. Urban participants had significantly higher infection positivity rates for COVID-19 (18.5% vs. 10.2%) and Flu A (29.2% vs. 1.8%). While overall usability ratings were high across both groups (>94%), rural participants had significantly lower odds of identifying invalid test results and were more likely to continue using tests after procedural errors. Conclusions: Despite strong usability ratings, diagnostic test comprehension differed by geography. Rural participants demonstrated notable gaps in recognizing invalid results, underscoring the need for targeted educational strategies and simplified instructions to ensure equitable test interpretation and public health response.

  • Open Access

    Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2

    by Anuradha Rao, Laura Johnson, Leda Bassit, Julie Sullivan, Heather B Bowers, Courtney Sabino, Seegar Swanson, Mark Griffiths, Cheryl Stone, Kaleb B McLendon, et al.

    Background: As the test verification core for the Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program (ITAP), we conducted independent bench- and field-based performance testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A&B lateral flow assays (LFAs) prior to formal clinical studies for Food and Drug Administration (FDA) submission. Methods: During bench testing, the limit of detection (LOD) was approximated using serially diluted panels of laboratory-propagated virus. In field studies, LFA results were interpreted by study participants, and sensitivity and specificity were determined using reverse transcription polymerase chain reaction (RT-PCR) (Xpert CoV-2/Flu/RSV plus) from a concurrent nasal swab as the reference standard. Results: Between February 2023 and February 2025, we tested 30 iterations of 14 LFAs. LODs were 53 277–1 393 314 genome equivalents (GE)/mL for SARS-CoV-2, 85 027–1 731 676 for influenza A, and 11 688–2 960 941 for influenza B. Field studies enrolled 27 to 126 participants per LFA with most enrolling at least 50 participants. When minimum 5 positive cases were enrolled, sensitivity ranged from 0.57–1.00 for SARS-CoV-2 and 0.64–0.85 for influenza A. Influenza B case enrollment was low. Specificity ranged from 0.91–1.00 across all targets. Eleven of 14 devices underwent at least two iterations of testing. Following ITAP assessment, 7 devices received FDA emergency use authorization, and 3 ultimately received de novo marketing approval or 510 (k) clearance. Conclusions: The ITAP enabled rapid feedback to federal agencies and manufacturers on the analytical and clinical performance of over-the-counter LFAs for SARS-CoV-2 and influenza, ultimately contributing to success in regulatory authorization or clearance.


  • Open Access

    Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers

    by Dunia Hatabah, Sneh Lata Gupta, Grace Mantus, Patrick Sullivan, Stacy Heilman, Andres Camacho-Gonzalez, Deborah Leake, Mimi Le, Mark Griffiths, Carson Norwood, et al.

    Background: Vaccines against COVID-19 target the spike protein. There is minimal information on longitudinal COVID-19 immune profiling in recovered versus naïve and vaccinated versus non-vaccinated healthcare workers (HCWs). Methods: This is a prospective longitudinal observational cohort of pediatric HCWs (pHCWs) conducted during 2020–2022 at an academic center, exploring the impact of COVID-19 vaccination on immunoglobulin G (IgG) antibody titers over time and cross-reactivity with other coronaviruses, including SARS-CoV-1, MERS-CoV, and seasonal coronaviruses (HCoV-HKU1 and HCoV-OC43). Results: A total of 642 pHCWs initially enrolled, and 337 participants had repeat IgG titers measured post-vaccine and post-booster. Most participants were female, median age range of 31–40 years. Anti-spike was higher in all vaccinated individuals versus non-vaccinated (p < 0.0001) and naïve versus infected (p < 0.0001). A single dose of vaccine was sufficient to attain maximum titers in recovered participants versus naïve who received both doses of vaccine. Anti-spike titers dropped significantly at 9 months after the primary series, whereas sustained anti-spike titers were observed at 9 months post-booster. Conclusions: All vaccinated pHCWs developed antibodies to spike. COVID-19 infection and/or vaccination yielded antibodies that cross-reacted to SARS-CoV-1, MERS-CoV, HCoV-HKU1, and HCoV-OC43. Anti-spike titers were more durable post-booster compared to the primary series. Longitudinal immune profiling of COVID-19 responses provides vital data to shape public health policies, optimize vaccine strategies, and strengthen pandemic preparedness.


  • Open Access

    Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study

    by Mark Griffiths, Dunia Hatabah, Patrick Sullivan, Grace Mantus, Travis Sanchez, Maria Zlotorzynska, Stacy Heilman, Andres Camacho-Gonzalez, Deborah Leake, Rawan Korman, et al.


  • Willingness to Accept Expedited COVID-19 Vaccine Research for Children Aged <12 Years After Adult Vaccine Approval

    by Ran D. Goldman, Jeffrey N. Bone, Renana Gelernter, Danna Krupik, Eileen J. Klein, Mark A. Griffiths, Ahmed Mater


  • Open Access

    Caregiver Willingness to Vaccinate Their Children against COVID-19 after Adult Vaccine Approval

    by Ran D. Goldman, Danna Krupik, Samina Ali, Ahmed Mater, Jeanine E. Hall, Jeffrey N. Bone, Graham C. Thompson, Kenneth Yen, Mark A. Griffiths, Adi Klein, et al.

    Vaccines against COVID-19 are likely to be approved for children under 12 years in the near future. Understanding vaccine hesitancy in parents is essential for reaching herd immunity. A cross-sectional survey of caregivers in 12 emergency departments (ED) was undertaken in the U.S., Canada, and Israel. We compared reported willingness to vaccinate children against COVID-19 with an initial survey and post-adult COVID-19 vaccine approval. Multivariable logistic regression models were performed for all children and for those p = 0.002). The most significant positive predictor of willingness to vaccinate against COVID-19 was if the child was vaccinated per recommended local schedules. Fewer caregivers plan to vaccinate their children against COVID-19, despite vaccine approval for adults, compared to what was reported at the peak of the pandemic. Older caregivers who fully vaccinated their children were more likely to adopt vaccinating children. This study can inform target strategy design to implement adherence to a vaccination campaign.


  • Open Access

    The RADx Tech Test Verification Core and the ACME POCT in the Evaluation of COVID-19 Testing Devices: A Model for Progress and Change

    by Eric J. Nehl, Stacy S. Heilman, David Ku, David S. Gottfried, Sarah Farmer, Robert Mannino, Erika Tyburski, Julie Sullivan, Allison Suessmith, Leda Bassit, et al.

    Faced with the COVID-19 pandemic, the US system for developing and testing technologies was challenged in unparalleled ways. This article describes the multi-institutional, transdisciplinary team of the “RADx SM Tech Test Verification Core” and its role in expediting evaluations of COVID-19 testing devices. Expertise related to aspects of diagnostic testing was coordinated to evaluate testing devices with the goal of significantly expanding the ability to mass screen Americans to preserve lives and facilitate the safe return to work and school. Focal points included: laboratory and clinical device evaluation of the limit of viral detection, sensitivity, and specificity of devices in controlled and community settings; regulatory expertise to provide focused attention to barriers to device approval and distribution; usability testing from the perspective of patients and those using the tests to identify and overcome device limitations, and engineering assessment to evaluate robustness of design including human factors, manufacturability, and scalability.


  • Open Access

    Covid‐19 will not “magically disappear”: Why access to widespread testing is paramount

    by Paul E. George, Claire L. Stokes, Leda C. Bassit, Ann Chahroudi, Janet Figueroa, Mark A. Griffiths, Stacy Heilman, David N. Ku, Eric J. Nehl, Traci Leong, et al.